Navigation Links
ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimer's Disease
Date:12/20/2007

PARIS, December 20 /PRNewswire-FirstCall/ -- ExonHit Therapeutics, a drug and diagnostic discovery company, announced today that it has obtained a regulatory approval to initiate a Phase 2 clinical trial of its therapeutic compound, EHT 0202, in patients with Alzheimer's disease. EHT 0202 is a compound, with a novel mechanism of action, which has shown benefits on memory and neuronal loss.

This will be the first Phase 2 clinical trial for EHT 0202, it will be a multi-center, double-blind trial, in which 135 patients will be randomized. The trial's primary endpoint is the safety and tolerability of the product when it is administered orally for a 3 month period in conjunction with an acetylcholinesterase inhibitor, the most common therapy used to treat Alzheimer's disease. The trial will also provide preliminary data on EHT 0202's clinical efficacy, in particular regarding its effects on cognition and behaviour.

Alzheimer's disease is a major public heath issue, with a patient population that is expected to grow rapidly in the near future because of the aging population. It is estimated that over 25 million people worldwide, including 860 thousand in France, suffer from Alzheimer's disease or assimilated pathologies. "Medical research has made significant progress in that field, as shown by the number of therapies now available, however their efficacy remains limited. There is thus a significant need for new and innovative therapies, which will not only provide symptomatic relief but also modify the disease's evolution by slowing or even stopping its underlying neurodegenerative process." stated Olivier Sol, MD, Clinical Director ExonHit.

"EHT 0202's pharmacological properties, linked to its GABA-A receptor modulating role, offer a promising approach to restoring the CNS processes that are altered in Alzheimer's disease, such as neuron degeneration and cognition. Indeed, this compound redirects the processing of APP (Amyloid Precursor Prot
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
2. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
3. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
4. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
5. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
6. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
7. Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
8. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
9. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
10. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
11. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  Franciscan St. Anthony Health-Crown ... for respiratory monitoring outside the operating room, ... in embracing state-of-the-art patient safety technology. ... breathing and can alert medical caregivers when ... amount of carbon dioxide the patient is ...
(Date:7/10/2014)... OAKS, Calif., July 10, 2014   Ceres, Inc ... and seed company, announced today financial results for the ... update on its business. Ceres reported that ... in product performance this growing season in Brazil, which ... affected the company,s sorghum evaluation areas for part of ...
(Date:7/10/2014)... extremely challenging because there are many genetic variants that ... Now investigators reporting in the July 3rd issue of ... describe a strategy that may help reveal how such ... environmental exposures to affect the development of the nervous ... predispose individuals to schizophrenia. , The work takes ...
(Date:7/10/2014)... the University of Illinois at Urbana-Champaign provides new ... of spin and heat at the nanoscale, and ... for data storage and information processing. , ... momentum. In a typical charge current, electrons, spin-angular-momentum ... explained David Cahill, a professor of materials science ...
Breaking Biology Technology:Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9New strategy could uncover genes at the root of psychiatric illnesses 2University of Illinois study advances limits for ultrafast nano-devices 2
... Companies Also Sign Manufacturing and Distribution Agreement, ... 15 Ranbaxy,Pharmaceuticals Inc. (RPI), a wholly ... today that it has reached several,agreements with ... capsules. The third agreement pertains to Omeprazole ...
... April 15 Arbios Systems, Inc.,(OTC Bulletin Board: ... authorization process in the European Union to pursue ... has engaged the British,Standards Institute (BSI), one of ... Company in its effort to obtain a CE ...
... Inc.,today announced the appointment of Fisher HealthCare as the ... the Hitachi, Hitachi,Roche P-Modular and Olympus chemistry analyzers to ... cleared by the U.S.,Food & Drug Administration (FDA) enabling ... The PLAC Test is the only blood test ...
Cached Biology Technology:Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation 2Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation 3Arbios Commences Process to Seek European Marketing Approval for SEPET(TM) 2Arbios Commences Process to Seek European Marketing Approval for SEPET(TM) 3Arbios Commences Process to Seek European Marketing Approval for SEPET(TM) 4diaDexus Selects Fisher HealthCare to Sell New Automated PLAC(R) Test 2diaDexus Selects Fisher HealthCare to Sell New Automated PLAC(R) Test 3
(Date:7/11/2014)... Using spider toxins to study the proteins that let ... say they have stumbled upon a biological tactic that ... insect plagues in a safe and environmentally responsible way. ... be lethal for one species and harmless for a ... target specific pests without harming beneficial species like bees. ...
(Date:7/10/2014)... In Santa Fe, Albuquerque, and other major cities in ... watered with treated municipal wastewater rather than precious potable ... more than 40% of all golf courses receive treated ... courses. , Additionally, golf courses and homeowners alike ... nutrient in fertilizer is nitrate. A New Mexico State ...
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3'Tailored' water -- the latest in lawn care 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... by a discovery about how chickens regulate their appetites. ... the signals sent from its stomach to its brain that ... Poultry farmers often have to restrict food for chickens ... can overeat, affecting their ability to reproduce. The ...
... has shown that obesity runs in families, and twin studies ... heritability estimates over 50%. 32 genes have been identified as ... genes alone cannot fully explain the high level of heritability ... individual differences in childhood body weight. This has led to ...
... to convention, vegetation, when well-maintained, can lower the rates ... robbery and burglary, in cities, according to a Temple ... Evidence from Philadelphia, PA," published in the journal, ... longstanding principle, particularly in urban planning, that you don,t ...
Cached Biology News:Appetite genes are key to better diets for poultry, study shows 2Study finds strong genetic component to childhood obesity 2Urban vegetation deters crime in Philadelphia 2
... using advanced automated high throughput microplate processing equipment that dispenses ... accommodate virtually any lot size of the following formats (with ... 8 and 12 well strips, ... 384 well microplate, 1536 ...
... are based on well-established periodate chemistry, ... and reproducible. This kit contains all ... or antibody, including ready-to-use buffers and ... HRP is supplied ready-to-use and requires ...
... Acridinium NHS ester can be ... nucleic acids. The covalently bound ... chemiluminescence in the presence of ... proteins can be used as ...
... hold up to 6 strain chambers with precise ... use design ensures that cells grow over long ... compression. This unit allows you to control the ... 64 unique strain settings. The instrument fits in ...
Biology Products: